1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Renal Cell Carcinoma: Global Drug Forecast and Market Analysis to 2028

Renal Cell Carcinoma: Global Drug Forecast and Market Analysis to 2028

  • February 2020
  • 160 pages
  • ID: 5878093
  • Format: PDF
  • GlobalData
Up to $9896 off Until Oct 31st 2020

Summary

Table of Contents

Search Inside

Renal Cell Carcinoma: Global Drug Forecast and Market Analysis to 2028

Summary
Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, making up 90-95% of all kidney cancer cases.Globally, RCC represents the sixth most frequently diagnosed cancer in men and 10th in women.

RCC consists of a heterogeneous group of tumors with distinct genetic and metabolic defects.The major histologic RCC subtype is ccRCC, which represents 80-95% of cases (as shown in Table 2).

Other forms of the disease, usually referred as non-clear cell RCC (nccRCC), include papillary RCC (PRCC), chromophobe RCC (ChRCC), translocation carcinoma, medullary carcinoma, and collecting duct carcinoma.At present, metastatic RCC (mRCC) is considered incurable, with only a small minority of patients achieving a complete response (CR) to treatment.

However, major advances in the treatment landscape within the past 15 years have significantly improved progression-free survival (PFS) and overall survival (OS).

The analyst is expecting a total of 7 new entrants to launch over the forecast period in the 8MM from 2018-2028 while specific marketed agents are expected to undergo label expansion.The competition will be particularly fierce in renal cell carcinoma, immune checkpoint inhibitors and combinations thereof competing for market share in the adjuvant setting and in fist-line treatment of metastatic RCC.

No drugs are currently in late development for nccRCC leaving the treatment of that population an unmet need within the forecast period.

KEY QUESTIONS ANSWERED

- Seven late-stage pipeline agents are going to enter the renal cell carcinoma market from 2018 onwards. What impact will these agents have on the market?
- Which of these drugs will have the highest peak sales, and why?
- What are the current unmet needs in renal cell carcinoma, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
- What is the market outlook in the 8MM from 2018-2028? Consideration of major patent expiries, launch of new premium priced agents and expected label expansions.
- What are the main corporate trends? Who are the current and future players?

Scope
- Overview of renal cell carcinoma including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline renal cell carcinoma market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting renal cell carcinoma therapeutics sales in the 8MM.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global renal cell carcinoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global renal cell carcinoma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global renal cell carcinoma market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the renal cell carcinoma therapeutics market from 2018-2028.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
30% Off

($10995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Kidney Cancer Therapeutics & Diagnostics Market- Growth, Trends, and Forecasts (2020-2025)

  • $ 4250
  • August 2020
  • 134 pages

The kidney cancer therapeutics & diagnostics market will show a rapid growth due to the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies. - According ...

  • World
  • Europe
  • Renal Cancer
  • Cancer
  • Industry analysis
  • Smoking Prevalence
  • Cause-Specific Mortality Rate

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on